Browse > Article
http://dx.doi.org/10.7181/acfs.2018.01886

Safety, efficacy, and onset of a novel botulinum toxin type A (Nabota) for the treatment of glabellar frown lines: a single-arm, prospective, phase 4 clinical study  

Song, Sinyoung (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)
Lee, Yeon Hoon (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)
Hong, Joon Pio (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)
Oh, Tae Suk (Department of Plastic and Reconstructive Surgery, Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
Archives of Craniofacial Surgery / v.19, no.3, 2018 , pp. 168-174 More about this Journal
Abstract
Background: Safety, efficacy, and time to onset of effect of botulinum toxin type A is of importance to persons who seek improvement in glabellar frown lines, but this has not been well studied. The aim of this study was to determine the safety, efficacy, and onset of action of a newly developed botulinum toxin type A (Nabota) for the treatment of glabellar frown lines. Methods: This was a single-arm, open-label, and phase 4 clinical study. Forty-two subjects with glabellar lines were treated with five times of intramuscular injection of 0.1 mL (4 U/0.1 mL) for a total of 20 U of Nabota. Efficacy and safety were assessed at 2, 3, 4, 5, and 14 days. Efficacy was assessed by the investigator and it was defined as a 1-point change on a 4-point scale. Results: Improvement in glabellar frown lines at maximum frown was observed in 85.4% of subjects 2 days after administration. Improvement in glabellar lines at rest was observed in 51.2% of subjects 2 days after administration, and the proportion of subjects showing improvement increased with time. No severe adverse events were recorded. Conclusion: Onset of action was observed in the majority of subjects by 2 days after administration of Nabota. In addition, Nabota was found to be safe and effective for the treatment of glabellar frown lines.
Keywords
Botulinum toxins, type A; Glabellar frown line; Safety; Efficacy; Onset;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Tsui JK. Botulinum toxin as a therapeutic agent. Pharmacol Ther 1996;72:13-24.   DOI
2 Pearce LB, First ER, MacCallum RD, Gupta A. Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon 1997;35:1373-412.   DOI
3 Kim CS, Jang WS, Son IP, Nam SH, Kim YI, Park KY, et al. Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle. Hum Exp Toxicol 2013;32:914-20.   DOI
4 Harii K, Kawashima M. A double-blind, randomized, placebocontrolled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg 2008;32:724-30.   DOI
5 Honeck P, Weiss C, Sterry W, Rzany B; Gladys study group. Reproducibility of a four-point clinical severity score for glabellar frown lines. Br J Dermatol 2003;149:306-10.   DOI
6 Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N; Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112:1089-98.
7 Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:840-9.   DOI
8 Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, et al. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg 2013;39(1 Pt 2):171-8.   DOI
9 Won CH, Kim HK, Kim BJ, Kang H, Hong JP, Lee SY, et al. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. Int J Dermatol 2015;54:227-34.   DOI
10 Beer KR, Boyd C, Patel RK, Bowen B, James SP, Brin MF. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol 2011;10:39-44.
11 Schlessinger J, Monheit G, Kane MA, Mendelsohn N. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A. Dermatol Surg 2011;37:1434-42.   DOI
12 Prager W, Bee EK, Havermann I, Zschocke I. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study. Clin Interv Aging 2013;8:449-56.
13 Blitzer A, Binder WJ, Aviv JE, Keen MS, Brin MF. The management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997;123:389-92.   DOI
14 Rappl T, Parvizi D, Friedl H, Wiedner M, May S, Kranzelbinder B, et al. Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol 2013;6:211-9.